Eddy Anglade
Vorstandsvorsitzender bei Tenpoint Therapeutics Ltd.
Profil
Eddy Anglade was the founder of Lux Biosciences, Inc. which was founded in 2006, where he served as Chief Medical Officer from 2011 to 2013.
He is currently the Chief Executive Officer & Director at Tenpoint Therapeutics Ltd.
since 2023.
Dr. Anglade's former positions include Medical Director at Roche Laboratories, Inc., Vice President-Clinical Development at Enzon Pharmaceuticals, Inc., and Chief Medical Officer at Astellas Institute for Regenerative Medicine from 2015 to 2016.
Dr. Anglade's education includes an undergraduate degree from The Trustees of Columbia University in The City of New York and a doctorate from Yale School of Medicine.
Aktive Positionen von Eddy Anglade
| Unternehmen | Position | Beginn |
|---|---|---|
Tenpoint Therapeutics Ltd.
 Tenpoint Therapeutics Ltd. BiotechnologyHealth Technology Tenpoint Therapeutics Ltd. is a British biotechnology company that specializes in developing engineered cell-based therapies and in vivo reprogramming to restore vision for individuals with degenerative ocular diseases. The company is based in Cambridge, UK and was founded in 2020. Tenpoint Therapeutics brings together experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. The company's focus is on replacing diseased cells with healthy ones to permanently restore vision. Eddy Anglade has been the CEO of the company since 2023. | Vorstandsvorsitzender | 12.07.2023 |
Ehemalige bekannte Positionen von Eddy Anglade
| Unternehmen | Position | Ende |
|---|---|---|
| OCATA THERAPEUTICS INC | Technik-/Wissenschafts-/F&E-Leiter | 10.02.2016 |
Lux Biosciences, Inc.
 Lux Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Lux Biosciences, Inc. provides therapies for treatment of ophthalmic diseases. It develops and commercializes medications for ophthalmic diseases. The company was founded by Ulrich M. Grau, Eddy Anglade, Clarke A. Atwell and Sidney L. Weiss in 2006 and is headquartered in Jersey City, NJ. | Gründer | 01.07.2013 |
Roche Laboratories, Inc.
 Roche Laboratories, Inc. Medical DistributorsDistribution Services Part of Roche Holding AG, Roche Laboratories, Inc. markets and sells pharmaceutical medications. The company is based in Nutley, NJ. | Technik-/Wissenschafts-/F&E-Leiter | - |
| ENZON PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Ausbildung von Eddy Anglade
| The Trustees of Columbia University in The City of New York | Undergraduate Degree |
| Yale School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ENZON PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Lux Biosciences, Inc.
Lux Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Lux Biosciences, Inc. provides therapies for treatment of ophthalmic diseases. It develops and commercializes medications for ophthalmic diseases. The company was founded by Ulrich M. Grau, Eddy Anglade, Clarke A. Atwell and Sidney L. Weiss in 2006 and is headquartered in Jersey City, NJ. | Health Technology |
Roche Laboratories, Inc.
Roche Laboratories, Inc. Medical DistributorsDistribution Services Part of Roche Holding AG, Roche Laboratories, Inc. markets and sells pharmaceutical medications. The company is based in Nutley, NJ. | Distribution Services |
Astellas Institute for Regenerative Medicine
 Astellas Institute for Regenerative Medicine Pharmaceuticals: MajorHealth Technology Astellas Institute for Regenerative Medicine engages in the development and commercialization of human pluripotent stem cell technology in the field of regenerative medicine. The company also have a preclinical development pipeline in areas outside of ophthalmology, including; autoimmune diseases, inflammatory diseases, and wound healing. The company was founded on May 18, 2000 and is headquartered in Marlborough, MA. | Health Technology |
Tenpoint Therapeutics Ltd.
Tenpoint Therapeutics Ltd. BiotechnologyHealth Technology Tenpoint Therapeutics Ltd. is a British biotechnology company that specializes in developing engineered cell-based therapies and in vivo reprogramming to restore vision for individuals with degenerative ocular diseases. The company is based in Cambridge, UK and was founded in 2020. Tenpoint Therapeutics brings together experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. The company's focus is on replacing diseased cells with healthy ones to permanently restore vision. Eddy Anglade has been the CEO of the company since 2023. | Health Technology |
